MYMD PHARMACEUTICALS INC (MYMD) Stock Price, Quote, News and Overview
NASDAQ:MYMD - Nasdaq - US62856X2018 - Common Stock - Currency: USD
MYMD Quote, Performance and Key Statistics
NASDAQ:MYMD (7/23/2024, 8:26:03 PM)
1.82
0 (0%)
The current stock price of MYMD is 1.82 USD. In the past month the price decreased by -2.15%. In the past year, price decreased by -94.48%.
MYMD Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About MYMD
Company Profile
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. The company is headquartered in Baltimore, Maryland and currently employs 9 full-time employees. The company went IPO on 2008-07-24. The firm is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
Company Info
MYMD PHARMACEUTICALS INC
855 N. Wolfe Street, Suite 601
Baltimore MARYLAND 08086 US
CEO: Christopher C. Schreiber
Employees: 9
Company Website: https://www.mymd.com/
Phone: 18568488698
MYMD PHARMACEUTICALS INC / MYMD FAQ
What is the stock price of MYMD PHARMACEUTICALS INC today?
The current stock price of MYMD is 1.82 USD.
What is the ticker symbol for MYMD PHARMACEUTICALS INC stock?
The exchange symbol of MYMD PHARMACEUTICALS INC is MYMD and it is listed on the Nasdaq exchange.
On which exchange is MYMD stock listed?
MYMD stock is listed on the Nasdaq exchange.
What is MYMD PHARMACEUTICALS INC worth?
MYMD PHARMACEUTICALS INC (MYMD) has a market capitalization of 4.20M USD. This makes MYMD a Nano Cap stock.
How many employees does MYMD PHARMACEUTICALS INC have?
MYMD PHARMACEUTICALS INC (MYMD) currently has 9 employees.
What are the support and resistance levels for MYMD PHARMACEUTICALS INC (MYMD) stock?
MYMD PHARMACEUTICALS INC (MYMD) has a support level at 1.79 and a resistance level at 1.82. Check the full technical report for a detailed analysis of MYMD support and resistance levels.
Should I buy MYMD PHARMACEUTICALS INC (MYMD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MYMD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MYMD, evaluating the profitability, health, valuation and growth aspects
- MYMD PHARMACEUTICALS INC (MYMD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MYMD PHARMACEUTICALS INC (MYMD) Sales and EPS estimates to see what analysts future expectations are.
- MYMD PHARMACEUTICALS INC (MYMD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MYMD PHARMACEUTICALS INC (MYMD) Insider and Institutional Ownership to learn about the owners and their transactions.
- MYMD PHARMACEUTICALS INC (MYMD) Stock Chart to make your own analysis
- MYMD PHARMACEUTICALS INC (MYMD) Latest news and press-releases to stay up to date.
Does MYMD PHARMACEUTICALS INC (MYMD) stock pay dividends?
MYMD does not pay a dividend.
When does MYMD PHARMACEUTICALS INC (MYMD) report earnings?
MYMD PHARMACEUTICALS INC (MYMD) will report earnings on 2024-08-12, after the market close.
What is the Price/Earnings (PE) ratio of MYMD PHARMACEUTICALS INC (MYMD)?
MYMD PHARMACEUTICALS INC (MYMD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.18).
MYMD Technical Analysis
MYMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MYMD. MYMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MYMD Financial Highlights
Over the last trailing twelve months MYMD reported a non-GAAP Earnings per Share(EPS) of -0.18. The EPS increased by 52.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.43% | ||
| ROE | -43.95% | ||
| Debt/Equity | 0 |
MYMD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to MYMD. The Buy consensus is the average rating of analysts ratings from 7 analysts.